Cholecystokinin and Psychiatric DisordersRole in Aetiology and Potential of Receptor Antagonists in Therapy

被引:0
|
作者
Jakov Shlik
Eero Vasar
Jacques Bradwejn
机构
[1] University of Tartu,Department of Psychiatry
[2] University of Tartu,Department of Physiology
[3] University of Toronto,Psychobiology and Clinical Trials Research Unit in Anxiety, Clarke Institute of Psychiatry
来源
CNS Drugs | 1997年 / 8卷
关键词
Panic Disorder; Cholecystokinin; Caerulein; Proglumide; Bioi Psychiatry;
D O I
暂无
中图分类号
学科分类号
摘要
Cholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in the highest levels in cortical and limbic structures and also in the basal ganglia. Two subtypes of CCK receptors have been described in the brain and gastrointestinal tissues. CCKA (alimentary subtype) receptors are mainly located in the gastrointestinal tract, regulating secretion of enzymes from the pancreas and emptying of the gallbladder. However, CCKA receptors are also found in several brain regions, with the highest densities in structures poorly protected by the haematoencephalic barrier (the area postrema, nucleus tractus solitarius and hypothalamus). The distribution of CCKB (brain subtype) receptors overlaps with the localisation of CCK and its mRNA in different brain areas, with the highest densities in the cerebral cortex, basal ganglia, nucleus accumbens and forebrain limbic structures.
引用
收藏
页码:134 / 152
页数:18
相关论文
共 50 条
  • [41] EFFECT OF CHOLECYSTOKININ RECEPTOR ANTAGONISTS ON VOLUNTARY FOOD-INTAKE IN CHICKENS
    RODRIGUEZSINOVAS, A
    MANTECA, X
    FERNANDEZ, AG
    FERNANDEZ, E
    GONALONS, E
    APPLIED ANIMAL BEHAVIOUR SCIENCE, 1994, 40 (3-4) : 319 - 323
  • [42] ANALOGS OF PROGLUMIDE AS HIGHLY POTENT AND SELECTIVE CHOLECYSTOKININ (CCK) RECEPTOR ANTAGONISTS
    JENSEN, RT
    ZHOU, ZC
    JONES, SW
    SETNIKAR, I
    ROVATI, LA
    GARDNER, JD
    GASTROENTEROLOGY, 1986, 90 (05) : 1476 - 1476
  • [43] STRUCTURAL FEATURES OF VARIOUS PROGLUMIDE-RELATED CHOLECYSTOKININ RECEPTOR ANTAGONISTS
    JENSEN, RT
    ZHOU, ZC
    MURPHY, RB
    JONES, SW
    SETNIKAR, I
    ROVATI, LA
    GARDNER, JD
    AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 251 (06): : G839 - G846
  • [44] EFFECTS OF CHOLECYSTOKININ RECEPTOR AGONIST AND ANTAGONISTS ON MORPHINE-DEPENDENCE IN MICE
    ZARRINDAST, MR
    MALEKZADEH, A
    REZAYAT, S
    GHAZIKHANSARI, M
    PHARMACOLOGY & TOXICOLOGY, 1995, 77 (06): : 360 - 364
  • [45] Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
    Han, Ying
    Yuan, Kai
    Zheng, Yongbo
    Lu, Lin
    NEUROSCIENCE BULLETIN, 2020, 36 (04) : 432 - 448
  • [46] Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
    Ying Han
    Kai Yuan
    Yongbo Zheng
    Lin Lu
    Neuroscience Bulletin, 2020, 36 : 432 - 448
  • [47] Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
    Ying Han
    Kai Yuan
    Yongbo Zheng
    Lin Lu
    Neuroscience Bulletin, 2020, 36 (04) : 432 - 448
  • [48] LACK OF COMPETITION BETWEEN 2 REPUTED PERIPHERAL CHOLECYSTOKININ RECEPTOR ANTAGONISTS FOR CENTRAL CHOLECYSTOKININ BINDING-SITES
    CLARK, CR
    DAUM, P
    HUGHES, J
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1985, 448 (JUL) : 581 - 582
  • [49] Are CRF receptor antagonists potential antidepressants?
    O'Brien, D
    Skelton, KH
    Owens, MJJ
    Nemeroff, CB
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2001, 16 (01) : 81 - 87
  • [50] The renoprotective potential of endothelin receptor antagonists
    Benigni, A
    Remuzzi, G
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (02) : 139 - 149